Pevion Fact Sheet Ju.. - Pevion Biotech AG

Pevion at a glance
Swiss, privately–owned,
clinical stage vaccine
development company
Product pipeline focusing on
major unmet medical needs
Vaccine candidates based on
clinically and commercially
validated carrier & adjuvant
technology (virosomes)
Industrial partnerships
established, one product
successfully out-licensed
Technology and product
portfolio protected by
extensive patent portfolio of
11 patent families
State-of-the-art, in-house
development and scalable
GMP process
Experienced management,
proven vaccine development
and biotech expertise
Company Fact Sheet
P E V I O N – B U I L T O N S O L I D G R O U N D
Pevion Biotech AG is a Swiss company active in one of the fastest growing
segments in the pharmaceutical industry: the vaccine market (CAGR approx.
25%). The Company develops vaccines for unmet medical needs based on its
clinically and commercially validated virosome technology, which functions
both as carrier and adjuvant. Virosomes belong to the established class of VLP
(virus-like particles) with successful products on the market such as Gardasil ®
(marketed by Merck) or Engerix-B ® (marketed by GSK). Two virosome-based
vaccines, Epaxal ® and Inflexal ® V (both marketed by Crucell Switzerland AG,
now a Johnson & Johnson company) are licensed in over 40 countries, and
more than 70 million doses of these vaccines have been commercially
distributed, thereby providing a solid safety and efficacy track record.
T O W A R D S N E W H O R I Z O N S
Virosomes are particularly well suited for addressing new vaccine indications.
They are a highly versatile toolbox-type system, allowing the use of difficult
antigens and/or molecular targets (e.g. peptides, proteins). Of elementary
importance, virosomes are the only VLP-based vaccines that are assembled in
a tightly controlled process in vitro and are therefore independent from any
host cell expression system. This results in products of well-defined
composition and high purity, which is essential for developing effective and
safe vaccines. Pevion has the in-house expertise and capability to develop its
candidate vaccines according to industry standards, including a state-of-the-art
and scalable GMP manufacturing process.
S T R A T E G I C F O C U S
J U L Y 2 0 1 1
Pevion’s product pipeline focuses on innovative vaccines for unmet medical
needs, which so far could not be addressed by any conventional treatment
approach. Consequently, all candidates have first-in-class and/or best-in-class
opportunities. While Pevion’s most advanced program, the malaria vaccine
PEV3, has already been out-licensed successfully after completion of a Phase II
study, the Company is now concentrating its efforts on its lead program PEV7,
a therapeutic vaccine against recurrent vulvovaginal candidiasis (RVVC), an
unrecognized but widespread and highly debilitating condition.
Discovery Optimization Preclinical Phase I Phase II Phase III
PEV7 i.m. Candida albicans (RVVC)
PEV7 i.vag. Candida albicans (RVVC)
PEV4 Respiratory syncytial virus (RSV)
PEV6 Breast cancer (HER2)
PEV3 Malaria - Product outlicensed
HIV - Indication / technology outlicensed
Pevion pipeline Q3 2011

Management Team
Evert Kueppers CEO
Christian Spyr Head of Clinical
Development &
Project Management
Mario Amacker Head of Process
Development &
Manufacturing
Christian Moser Head of Research
Board of Directors
Didier Hoch Chairman,
Ex- Chairman of
Sanofi Pasteur MSD
Jean-Paul Prieels Ex-Senior VP R&D of
GSK Biologicals
Achim Kaufhold CMO Basilea
Pharmaceutica
Daniel Richner BZ Fund Managemt
Daniel Erne CTO Bachem Hold
Klaus Breiner BB Biotech Ventures
Pevion Biotech AG
Worblentalstrasse 32
3063 Ittigen
Switzerland
Phone +41 31 550 44 44
Fax +41 31 550 44 45
info@pevion.com
www.pevion.com
R E C E N T M I L E S T O N E S
PEV7 therapeutic RVVC vaccine achieved positive Phase I interim results
PEV4 RSV vaccine achieved preclinical proof-of-concept in two animal
models: Mice and Cotton rats were protected against a live virus challenge,
no pathological events were detected
Licensee Mymetics announced positive Phase I trial results with virosomebased
HIV vaccine
Development of a mucosal galenic, freeze-dried version of virosomes
enabling among others vaginal capsule formulation
New Chairman with relevant vaccine development / launch experience
New Board member with portfolio and vaccine development experience
Strengthened management with experienced vaccine development
specialist and biotech-proven CEO
Additional CHF 10 million funding
Partnership with US vaccine company
S T R O N G T R A C K R E C O R D
Pevion’s track record to date proves the company’s capability to translate its
assets into successful product development and to generate added value for
its shareholders.
Products developed and manufactured by Pevion were tested in a total of 7
Phase I and Phase II trials
To date, 4 products demonstrated immunogenicity in human; 5 peptide
and 2 protein antigens validated
Excellent safety and tolerability in human, no failure ever
PEV3 Malaria vaccine successfully out-licensed after Phase II
Technology and product design out-licensed for HIV vaccine; now
successful in clinical Phase I
11x patent families, in-depth know how and trade secrets
Platform improvements & new IP (freeze-dried formulation, mucosal
galenic, immunostimulation)
GMP compliance status granted by Swissmedic
F I N A N C I A L S U M M A R Y
Pevion was founded in 2002 by Bachem Holding and Berna Biotech, which
provided a total of CHF 20 million as a start- up capital. Berna Biotech was
acquired by Crucell N.V. (now a Johnson & Johnson subsidiary) in 2006. In
August 2007, the Company closed a CHF 15 million series A financing round
with new investors BZ Bank Aktiengesellschaft, BB Biotech Ventures and Core
Capital Partners as well as the existing investor Bachem AG. Crucell was
bought out in November 2007. In September 2010, Pevion secured additional
CHF 10 million in financing from its current investors.
C O N T A C T
To request further information, please contact:
Julian Wagner, PhD, Business Development
info@pevion.com, Tel: +41 31 550 44 44